Compass Completes FDA NDA Submission for Psilocybin Depression Therapy
CMPS sits 82% above its 52-week low of $4.88.
Summary
Compass finished submitting its New Drug Application to the FDA for COMP360 psilocybin in treatment-resistant depression, moving the program from clinical data into the regulatory review phase. This is the key gating step before any U.S. approval, and it follows the positive Phase 3 readouts reported in September. The company says it has a fully scaled commercial organization ready to support launch if approved. The NDA covers a market of roughly 4 million U.S. TRD patients, fewer than 5% of whom are currently on a TRD-indicated treatment. Approval is not assured, and the drug still needs DEA and state rescheduling before it can be commercialized. The FDA review timeline is the next milestone to track.
At the time of this announcement, CMPS was trading at $8.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.88 to $15.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.